Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all- cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Apogee is also developing APG273, a combination therapy consisting of zumilokibart and APG333, an anti- TSLP antibody, for asthma. Phase 1 data indicated APG333 maintained suppression of type 2 inflammatory markers for up to s ...

Acquisition of Apogee Therapeutics June 22, 2026 1 Forward-Looking Statements and Non-GAAP Financial Information This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements other than statements of historical fact, including statements regarding market and industry prospects and fu ...